Evidence map›Paper›PMID 34591131›Full record

ReviewDer Internist2021

[Obesity treatment-legal and illegal drugs and the future].

H Hauner

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Bioscience of microbiota, food and health · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

H HaunerInstitut für Ernährungsmedizin, Klinikum rechts der Isar, München, Deutschland. hans.hauner@tum.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity and its comorbidities represent a worldwide growing health challenge. In Germany, at least 15 million people are suffering from this disease. To date, lifestyle modification is the most frequently used treatment modality, but offers only limited success concerning both the extent and the sustainability of weight loss, while surgical interventions are restricted to people with severe obesity (body mass index ≥40 kg/m

Indexed as

Anti-Obesity AgentsIllicit DrugsHumansObesityOrlistatWeight LossAnti-Obesity AgentsIllicit DrugsOrlistatDiabetes mellitus, type 2Dietary supplementsLifestyle interventionPharmacotherapyWeight loss

Identifiers

PMID34591131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.